Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Stifel 2025 ...

B. Riley has initiated coverage of Vanda Pharmaceuticals (VNDA) at buy saying that the company is currently trading at a ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2025 on ...

Fintel reports that on November 5, 2025, B. Riley Securities initiated coverage of Vanda Pharmaceuticals (NasdaqGM:VNDA) with ...

Shares of Vanda Pharmaceuticals fell after the company reported a third-quarter loss that wider than a year ago and dropped the high end of its full-year revenue view. The stock was 18% lower, at ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...

Discover Vanda Pharmaceuticals' Q3 2025 results: strong Fanapt growth, updated guidance, and pipeline milestones.

With a win in a D.C. appeals court, Vanda Pharmaceuticals has earned a point over the FDA in the yearslong face-off between the drugmaker and the drug regulator. Vanda has been fighting to market its ...

Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has issued a complete response letter to Vanda Pharmaceuticals indicating it cannot approve the ...

On CNBC's "Mad Money Lightning Round," Jim Cramer discussed Apollo Global, National Fuel Gas, Main Street Capital and Vanda ...